Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
Purpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods. Melanoma survivors were identified within two study p...
Saved in:
Main Authors: | Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, Jan L. Bernheim, Bart Neyns |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2020/2192480 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
by: A. A. Formozo, et al.
Published: (2021-01-01) -
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Bartosz Chmielowski
Published: (2013-01-01) -
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012-01-01) -
Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01) -
Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)